Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aliskiren in Hypertensive IgA Nephropathy
NCT01184599Phase 4Unknown
- Sponsor
- Kagawa University
- Start
- Jun 2010
- Primary completion
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aliskiren in IgA nephropathy (IgAN), sponsored by Kagawa University. Primary endpoints: Renal function (Creatinine clearance) at 1 year and Urinary protein at 1 year. Status: unknown.
02
Drugs
aliskiren
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT01184599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01184599.